ZYUS Life Sciences Strengthens Software Patent Portfolio Supporting Clinical Development

July 22, 2021 11:35 UTC

 

Three newly granted software patents enable ZYUS to leverage patient-focused, proprietary clinical and healthcare technology solutions to optimize ZYUS’ clinical trial development

 

SASKATOON, Saskatchewan--(BUSINESS WIRE)-- ZYUS Life Sciences Inc. ("ZYUS"), a Canadian-based life sciences company leading scientific research and development in phyto-therapeutics, announced today that its wholly owned U.S. subsidiary, ZYUS Life Sciences U.S. Ltd. (“ZYUS U.S.”), has received one patent allowance notification and two patent issuances from the United States Patent and Trademark Office (USPTO). Advancement of these software patents will further strengthen ZYUS’ clinical trial program by ensuring access to proprietary clinical and healthcare technology solutions.

Notice of Allowance for U.S. Patent Application No. 14/945,991 (a continuation, in part, of PCT/US2014/040064) entitled: Schedule-Based Electronic Medical Record Modules, Applications, and Uses Thereof was received by the Company in late June, 2021 and issuance fees were paid on July 19, 2021. This patent covers computer programing that can be used to assemble a database of electronic data modules. This technology can be used to, among other things, identify, recruit and track participants in clinical trials.

In addition, U.S. Patent No. 11,069,430 entitled: Patient State Representation Architecture and Uses Thereof was issued July 20, 2021. This patent covers the use of a centralized system that can, among other things, include patient information collected from diagnostic devices used by patients (such as fitness trackers and consumer diagnostic equipment), allow multiple healthcare practitioners to view a patient’s health records, provide researchers with access to de-personalized patient information or be used in conjunction with applications to perform interactive health evaluations and recommend actions to maintain, or restore, a patient’s health.

Patient-First Healthcare Technology Solutions

Advancement of these patents, together with the recent issuance of U.S. Patent No.11,024,304 Virtual Assistant Companion Devices and Uses Thereof on June 1, 2021, further strengthens ZYUS’ clinical program by protecting important intellectual property used in ZYUS’ healthcare technology platform, which has also received HITRUST CSF® certification in the United States. This continued momentum accretes additional strength to the assets of Revon Systems, Inc. which ZYUS completed in 2019.

“In keeping with ZYUS’ mission to advance the science of well-being, we intend to leverage these patents through our technology platforms to optimize our clinical trials through smart registry services, real world evidence collection and patient reported outcomes tracking for identifying, recruiting and monitoring participants,” said ZYUS CEO Brent Zettl. “While this technology will allow us to increase clinical trial efficiency, it also further illustrates our commitment to patient privacy by giving us the ability to systematically depersonalize patient information accessed by researchers.”

Prospective patients or healthcare practitioners (HCPs) seeking more information on ZYUS, or its products, can visit ZYUS.ca, or speak to a member of the ZYUS Patient Care Centre at 1-833-713-CARE (2273).

About ZYUS Life Sciences Inc.

ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of innovative cannabinoid-based therapeutics and product candidates. Through clinical research and IP development, we intend to deliver high-quality oils, soft gels, topical creams and other cannabinoid-based therapeutics and product candidates to patients worldwide. The ZYUS vision is to elevate cannabinoids as a standard of care and expand the potential of protein-based formulations in pursuit of a transformational impact on patients’ lives. ZYUS: Advancing the Science of Well-Being. Visit www.zyus.com.

Forward-Looking Information

This news release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of ZYUS to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These forward-looking statements include, but are not limited to, expectations with respect to the functionality of the technology (that is the subject to the patents noted in this press release) to our current clinical trial and proposed future trials, business plans, product lines, intellectual property strategy, research activities and the prospects for regulatory approval, ability to maintain HITRUST CSF® certification of the technology that is the subject of our patents, commercializing or selling any product or drug candidates. Research and clinical trial programs are of an experimental nature and no particular results can be guaranteed due to a number of factors and risks.

Often, but not always, forward-looking statements can be identified by the use of words such as “expects,” “expected,” “expectation,” “anticipates,” “believes,” “intends,” “estimates,” “predicts,” “continues,” “potential,” “targeted,” “plans,” “possible,” and similar expressions, or statements that events, conditions or results “will,” “may,” “could,” “would” or “should” occur or be achieved, or the negative of these terms or other comparable terminology. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified, including risks related to: the actual functionality and our ability to maintain HITRUST CSF® certification of the technology that is the subject of our patents, potential impacts due to the COVID-19 pandemic such as delays in regulatory review; and the success of future product advancements, including the success of future clinical trials and patent applications. Consequently, actual results may differ materially from those expressed or implied by such forward-looking statements, and readers should not place undue reliance on the forward-looking statements and information contained in this press release.

Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. ZYUS does not assume any obligation to update or revise any forward-looking statements or information respecting the proposed research or results therefrom and development or certification of technology, whether written or oral, that may be made, from time to time, by us, or on our behalf, except as required by applicable law.

Contacts

ZYUS Media Inquiries
media@zyus.com
1-833-515-5500

ZYUS Investor Relations
Bruce M. Mann
investors@zyus.com
1-888-651-9987

 
 

Source: ZYUS Life Sciences Inc.

Back to news